Thursday, June 11, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Atherosclerosis Β· Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp trial registry β€” 217 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website β†— All projects Drug pipeline News & analysis
Intelligence Β· Clinical Trials

MSD Merck Sharp clinical trials

Registry index of 217 ClinicalTrials.gov studies linked to MSD Merck Sharp programs β€” each row shows trial ID, program name, phase, status, and indication.

MSD Merck Sharp trial registry β€” 217 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for MSD Merck Sharp.

  1. MS201924_0003 β€” Phase 1

    Clinical update

  2. MK-3475A-F11 β€” Phase 2

    Clinical update

  3. MK-3475-905 β€” Phase 3

    Clinical update

  4. V940-007 β€” Phase 3

    Clinical update

  5. MS200569_0065 β€” Phase 1

    Clinical update

  6. MK3475-054 β€” Phase 3

    Clinical update

  7. MK-8294-001 β€” Phase 1

    Clinical update

  8. MK-4482-023 β€” Phase 3

    Clinical update

Trial registry

217 studies
  3. 2022-501374-19-00

    MK-2140-006

    Phase 2 active small_molecule

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    CTIS β†—
  28. 2023-504931-42-00

    MK-1026-003

    Phase 2 active small_molecule

    Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; WaldenstrΓΆm’s macroglobulinemia

    CTIS β†—
  35. 2023-505177-32-00

    V940-004

    Phase 2 active small_molecule

    Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.

    CTIS β†—
  44. 2023-505712-37-00

    V940-007

    Phase 3 active small_molecule

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    CTIS β†—
  82. 2023-508323-12-00

    MK-2870-020

    Phase 3 active small_molecule

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    CTIS β†—
  86. 2023-508683-30-00

    V503-021

    Phase 3 active small_molecule

    ​9vHPV vaccine is indicated in females β‰₯ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    CTIS β†—
  91. 2023-509136-25-00

    MK3475-054

    Phase 3 active small_molecule

    Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)

    CTIS β†—
  96. 2023-509542-35-00

    MK-4830-001

    Phase 1 active other

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    CTIS β†—
  107. 2024-510969-42-00

    MK-3475A

    Phase 2 active small_molecule

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    CTIS β†—
  118. 2024-512135-80-00

    MK-7902-013

    Phase 2 active small_molecule

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    CTIS β†—
  135. 2024-514376-40-00

    MK-1022-010

    Phase 2 active small_molecule

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    CTIS β†—
  155. 2024-516870-31-00

    MK-8294-001

    Phase 1 active other

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    CTIS β†—
  211. 2025-524160-38-00

    MK-6482-043

    Phase 3 active small_molecule

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2Ξ± related Genetic Alterations

    CTIS β†—

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.